Reference - Detail
| RRC ID | 65421 |
|---|---|
| Author | Ofuji K, Saito K, Suzuki S, Shimomura M, Shirakawa H, Nobuoka D, Sawada Y, Yoshimura M, Tsuchiya N, Takahashi M, Yoshikawa T, Tada Y, Konishi M, Takahashi S, Gotohda N, Nakamoto Y, Nakatsura T. |
| Title | Perioperative plasma glypican-3 level may enable prediction of the risk of recurrence after surgery in patients with stage I hepatocellular carcinoma. |
| Journal | Oncotarget |
| Abstract |
Glypican-3 (GPC3) is a glycosylphosphatidylinositol-anchored cell surface protein overexpressed in hepatocellular carcinoma(HCC), and its overexpression is associated with poor prognosis. The diagnostic potential of GPC3 as a serum marker has been reported. In the present study, we evaluated the usefulness of plasma GPC3 as a predictor for recurrence after surgical resection in stage I HCC patients by newly developed an enzyme-linked immunosorbent assay (ELISA) system. Current study demonstrated that high levels of preoperative plasma GPC3 patients tended to experience postoperative recurrence. On the other hand, pre- and postoperative plasma GPC3 positivity of non-recurrence patients was very low. Moreover, even after surgery, approximately half of patients who experienced recurrence were positive for plasma GPC3. Postoperative plasma GPC3 positivity was significantly correlated with worse recurrence-free survival. Immuohistochemical analysis also showed positive rate of GPC3-expression in HCC was higher in recurrence patients than in non-recurrence patients. These results suggested that both pre- and postoperative plasma GPC3 levels may be accurate predictors for recurrence after curative resection of early-stage HCC. It should be noted that the current study only examined a small number of cases; thus, a larger sample size is necessary to validate GPC3 as a predictor for HCC recurrence. |
| Volume | 8(23) |
| Pages | 37835-37844 |
| Published | 2017-6-6 |
| DOI | 10.18632/oncotarget.14271 |
| PII | 14271 |
| PMID | 28035063 |
| PMC | PMC5514954 |
| MeSH | Adult Aged Aged, 80 and over Carcinoma, Hepatocellular / genetics* Carcinoma, Hepatocellular / pathology Carcinoma, Hepatocellular / surgery Enzyme-Linked Immunosorbent Assay / methods* Female Glypicans / blood* Glypicans / metabolism Humans Immunohistochemistry / methods* Liver Neoplasms / genetics* Liver Neoplasms / pathology Liver Neoplasms / surgery Male Middle Aged Neoplasm Recurrence, Local / metabolism* Neoplasm Staging Prognosis Risk |
| IF | 5.168 |
| Altmetric score |
オルトメトリクス指標項目
|
| The most frequently cited source | Patent(IFI CLAIMS) |
| Total number of mentions | 1 |
| Altmetric score changes over past 6months | 0.0 |
| Resource | |
| Human and Animal Cells | SP2/0-Ag14(RCB0209) |